Tivicay FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 28, 2021.
Tivicay (dolutegravir) is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI) indicated for use in combination with other antiretroviral (ARV) agents for the treatment of HIV-1.
Development Timeline for Tivicay
|Jun 12, 2020||Approval FDA Approves Tivicay PD (dolutegravir) Once-Daily Dispersible Tablet Formulation for Children with HIV|
|Aug 12, 2013||Approval FDA Approves Tivicay (dolutegravir) to Treat HIV Infection|
|Dec 18, 2012||ViiV Healthcare Announces Regulatory Submissions for Dolutegravir in the EU, US and Canada|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.